Promente Clinical Research Center
Psilocybin therapy research in treatment-resistant depression
What TRD means and how COMP360 is being studied in controlled clinical protocols.
What is treatment-resistant depression?
Treatment-resistant depression, often abbreviated as TRD, describes depressive symptoms that do not improve sufficiently after at least two adequate antidepressant treatment attempts.
For people living with TRD, everyday functioning can remain very difficult despite standard treatment. This is why new therapeutic approaches are being studied in carefully controlled clinical trials.
Psilocybin-assisted therapy research
Psilocybin is a substance that occurs naturally in some mushroom species. In clinical research, synthetic psilocybin is studied under controlled conditions together with structured psychological support.
The purpose of this research is to evaluate safety, tolerability and efficacy, not to offer an uncontrolled or routine service.
COMP 006 at Promente
Promente participates in COMP 006, a study evaluating COMP360 for people with treatment-resistant depression. Participation depends on protocol-specific eligibility criteria and medical assessment.
The study involves cooperation with a psychiatrist and therapist in a clinical setting, with study-related costs covered according to the protocol.